Comparative study of perindopril and perindopril metabolite pharmacokinetics using the HPLC/MS method

Perindopril is a prodrug which is converted to an active metabolite perindoprilat in the human organism. The present study led to the development of a fast and easily reproducible procedure for simultaneous detection of perinoprilat and its metabolite in plasma using HPLC with mass-spectrometric detector (LC-MS). Detection of the target substance was performed using atmospheric pressure electrospray ionization (API-ES) techniques in negative polarity in two modes: SIM1, ion, m/z=368,10 for perindopril and SIM2, ion, m/z=339,30 for perindoprilat. Retention time of perindopril was about 2,4 min, for perindoprilat - about 1,4 min. Sample processing was performed using solid-phase extraction. The method’s limit of quantification was equal to 1 ng/ml for perindopril and 1 ng/ml for perindoprilat. The developed procedure was used to analyse pharmacokinetics and bioequivalence of medicines containing 8 mg of perindopril. Values of all calculated pharmacokinetic parameters had no statistically meaningful differences. Confidence intervals obtained fall within bioequivalence criterion (80-125% for AUC and 75-133% for Сmax и Cmax/AUC). The medicines under analysis were found to be bioequivalent.

периндоприл, периндоприлат, ВЭЖХ-МС, фармакокинетика, биоэквивалентность, perindopril, perindoprilat, HPLC-MS, pharmacokinetics, bioequivalence

1. Russian national guidelines for the diagnosis and treatment of hypertension. Second revision. Kardiovaskulyarnaya terapiya i profilaktika 2004; (6) (in Russian).

2. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; (289): 2560–72.

3. Zhuchkova, Litsareva EA, Samoylova EL, Spivak NL, eds. Vidal handbook. Moscow: AstraFarmServis; 2003 (in Russian).

4. Nirogi RV et al. High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. Rapid Commun Mass Spectrom. 2006; 20(12): 1864–70.

5. Jain DS et al. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 837(1–2): 92–100.

6. Louis WJ, Workman BS, Conway EL et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril inhypertensive subjects. J Cardiovasc Pharmacol. 1992; 20(3): 505–11.

7. Van den Berg H, Resplandy G, de Bie AT et al. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. J Pharm Biomed Anal. 1991; 9(7): 517–24.

8. Maurer HH, Kraemer T, Arlt JW. Screening for the detection of angiotensinconverting enzyme inhibitors, their metabolites, and AT II receptor antagonists. Ther Drug Monit. 1998; 20(6): 706–13.

9. Conducting qualitative research of bioequivalence of drugs. Methodical instructions. The Ministry of Health and Social Development of the Russian Federation; 2008 (in Russian).